As more and more delivery firms set their sights on the specialty pharma sector, existing specialty players are increasingly abandoning established licensing strategies in favour of developing drugs in-house to compete.
Under pressure to respond to the spread of HIV in the developing
world, Gilead has signed non-exclusive licence agreements with
eight Indian generic companies for the manufacture of Viread
(tenofovir disoproxil fumarate), its popular...
Biotechnology firm Gilead has acquired Raylo Chemicals, a Canadian
production unit of active pharmaceutical ingredients (APIs) and
advanced intermediates, from Degussa for €115m, seeking to bring
more manufacturing capacity and expertise...